11月30日，徠卡顯微系統(tǒng)全球總裁Annette Rinck、首席技術(shù)官兼全球研發(fā)副總裁Dirk Voelkel、中國(guó)區(qū)總經(jīng)理章越、醫(yī)療部全國(guó)銷(xiāo)售總監(jiān)賈斌斌一行蒞臨我院，實(shí)地考察了我院的設(shè)備、服務(wù)和醫(yī)療技術(shù)，深入了解了國(guó)內(nèi)眼科的臨床和科研需求，探討了行業(yè)發(fā)展趨勢(shì)和未來(lái)合作方向。愛(ài)爾眼科上海總院CEO陳勝藍(lán)、愛(ài)爾眼科上海總院副院長(zhǎng)李文生、上海愛(ài)爾清亮眼科醫(yī)院CEO蘇怡、愛(ài)爾眼科上海總院屈光科專(zhuān)家邵清出席了本次交流會(huì)。

On 30th November, Dr. Annette Rinck, President of Leica Microsystems, Dirk Voelkel, Vice President Global R&D and Chief Technology Officer (CTO), Zhang Yue, General Manager of Leica Microsystems China, and Jia Binbin, National Sales Director of the Medical Department, and their group visited AIER Eye Hospital Shanghai and inspected our equipment, services and medical technology, and gained an in-depth understanding of the clinical and scientific research needs of Chinese ophthalmology, and discussed industry development trends and future cooperation directions.

Chen Shenglan, CEO of AIER Eye Hospital Shanghai, Li Wensheng, Vice President of AIER Eye Hospital Shanghai, Su Yi, CEO of Shanghai AIER Qingliang Eye Hospital, and Shao Qing, refractive expert of AIER Eye Hospital Shanghai, attended this meeting.

在相關(guān)領(lǐng)導(dǎo)的陪同下，Annette Rinck女士一行參觀了愛(ài)爾眼科上海總院檢查區(qū)、特需醫(yī)療部等，詳細(xì)了解了我院的醫(yī)療設(shè)備和服務(wù)情況，還現(xiàn)場(chǎng)了解了顯微鏡在我院的使用情況，并與醫(yī)院專(zhuān)家、工作人員進(jìn)行了親切交流。

Dr. Annette Rinck and her party visited the examination area and the International Medical Services Department of AIER Eye Hospital Shanghai, and visited our hospital's medical equipment and services, and the use of microscopes in our hospital, and communicated with the experts and staff.

Annette Rinck女士對(duì)我院完善的醫(yī)療體系、人性化的就診流程以及各類(lèi)眼科診療設(shè)備的先進(jìn)性給予了高度評(píng)價(jià)，同時(shí)對(duì)醫(yī)院現(xiàn)代化、規(guī)范化、標(biāo)準(zhǔn)化的建設(shè)成果贊賞有加。

Dr. Annette Rinck praised our hospital's medical system, humanized medical treatment process and various ophthalmic diagnosis and treatment equipment. She also praised the hospital's modernization and standardization construction.

隨后雙方就眼科醫(yī)學(xué)領(lǐng)域的發(fā)展趨勢(shì)、技術(shù)創(chuàng)新和合作模式等方面進(jìn)行了廣泛的交流和探討。

Subsequently, the two parties discussed the development trends, technological innovation and cooperation models in the field of ophthalmology. 

據(jù)愛(ài)爾眼科上海總院CEO陳勝藍(lán)介紹，愛(ài)爾眼科上海總院依托愛(ài)爾集團(tuán)1+8+N的戰(zhàn)略規(guī)劃，以建設(shè)國(guó)家級(jí)眼科醫(yī)學(xué)中心為愿景，致力于引進(jìn)國(guó)內(nèi)外前沿的眼科技術(shù)，運(yùn)用先進(jìn)的醫(yī)療服務(wù)管理理念，堅(jiān)持專(zhuān)業(yè)化、規(guī)范化、精細(xì)化、智能化的發(fā)展之路，不斷深化醫(yī)院管理內(nèi)涵建設(shè)，為廣大患者提供高水平的醫(yī)療技術(shù)、高標(biāo)準(zhǔn)的醫(yī)療服務(wù)，高效能的醫(yī)療保障，不斷推動(dòng)和助力眼科事業(yè)的高質(zhì)量發(fā)展。

According to Chen Shenglan, CEO of AIER Eye Hospital Shanghai, AIER Eye Hospital Shanghai relies on AIER Eye Hospital Group's “1+8+N” eye care service network. Under this strategy, the Group intends to build 1 world-class eye hospital, 8 national and regional eye center, and accelerate the establishment and development of eye medical institutions. It is expected that these efforts will improve the ophthalmic medical technology in China, and enable AIER to catch up with and even surpass advanced international levels, gain a good reputation among patients, and sustain a steady and consistent business level. 

會(huì)議中，Annette Rinck女士對(duì)愛(ài)爾眼科集團(tuán)的顯微鏡使用情況進(jìn)行了了解，徠卡中國(guó)區(qū)總經(jīng)理章越表示顯微鏡已經(jīng)成為了眼科手術(shù)中不可或缺的工具，徠卡將在“一體化術(shù)中OCT”、“助手鏡”、“AI人工智能”三個(gè)方面不斷優(yōu)化顯微鏡系統(tǒng)，為更多疑難眼病患者做出自己的貢獻(xiàn)。愿在未來(lái)的日子里，雙方進(jìn)一步加強(qiáng)交流與合作，在各自行業(yè)領(lǐng)域繼續(xù)領(lǐng)跑，為國(guó)內(nèi)眼科事業(yè)攀登新高峰做出貢獻(xiàn)。

Mr. Zhang Yue, conveyed the pivotal role of microscopes in ophthalmic surgeries during a meeting where Dr. Annette Rinck explored the utilization of these devices at the AIER Eye Hospital Group. Mr. Yue expressed that microscopes have evolved into indispensable tools in the field, emphasizing Leica Microsystems's commitment to ongoing optimization in three key areas: "Integrated OCT Surgery," "Assistive Mirrors," and "AI". These advancements aim to contribute significantly to the diagnosis and treatment of challenging eye conditions. Both parties envision a strengthened collaboration in the future, aspiring to maintain leadership positions in their respective industries. Their joint efforts are poised to make substantial contributions to the advancement of ophthalmology in China, ultimately enhancing healthcare services for patients.

最后，愛(ài)爾眼科上海總院CEO陳勝藍(lán)先生表示，希望未來(lái)雙方不斷加強(qiáng)更深層次的交流，為醫(yī)技人員帶來(lái)便利和效率，為廣大患者提供更安全、更精準(zhǔn)的診療服務(wù)。

Finally, Mr. Chen Shenglan, expressed his hope for continuous and deeper-level collaboration in the future. He aims to bring convenience and efficiency to medical professionals and provide a safer, more precise diagnostic and treatment service for a wider range of patients.

了解更多：徠卡顯微